他汀类药物在入院前的使用与心血管疾病或危险因素患者 COVID-19 严重程度降低的相关性。
Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors.
机构信息
Department of Cardiology, Tokai University School of Medicine.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine.
出版信息
Circ J. 2021 May 25;85(6):939-943. doi: 10.1253/circj.CJ-21-0087. Epub 2021 Apr 29.
BACKGROUND
Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).
METHODS AND RESULTS
In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.
CONCLUSIONS
This study suggests the potential benefits of statins use against COVID-19.
背景
心血管疾病和/或危险因素（CVDRF）已被报道为严重的 2019 年冠状病毒病（COVID-19）的危险因素。
方法和结果
我们从日本的 CLAVIS-COVID 数据库中总共选择了 693 例有 CVDRF 的患者，共 1518 例。平均年龄为 68 岁（35%为女性）。入院时报告有 31%的患者使用他汀类药物。尽管他汀类药物使用者有更多的合并症，如糖尿病，但他汀类药物使用者的体外膜氧合（ECMO）插入（1.4%比 4.6%，比值比[OR]：0.295，P=0.037）和感染性休克（1.4%比 6.5%，OR：0.205，P=0.004）发生率较低。
结论
本研究提示他汀类药物可能对 COVID-19 有潜在益处。
Zotero 插件